Clinical trials in womens cancers

我们目前正在分析来自临床试验07 C 0058-贝伐单抗和索拉非尼治疗卵巢癌的2期研究以及贝伐单抗和达沙替尼的1期研究09-C-0019的标本和数据。作为一个分支，我们开设了19-C-0025，以收集NCI其他方案入组的癌症患者的血液和积液（胸膜和腹膜）。其他临床试验正在概念阶段开发或正在接受IRB审查。在WMB，我与Jung-min Lee和Stan Lipkowitz合作，担任其他几项临床试验的副研究员。我还与Diana比安奇合作进行了一项临床试验，以调查胎儿核型正常的孕妇中异常cfDNA的来源。另一项合作测试了二甲双胍对Li Fraumeni综合征患者的代谢作用，一项更大规模的国际临床试验正在开发中，以测试这种药物作为预防LFS患者癌症的策略。

We are currently in the process of analyzing specimens and data from clinical trials 07C0058 - Bevacizumab and Sorafenib phase 2 in ovarian cancer; and 09-C-0019 phase 1 study of bevacizumab and dasatinib. As a Branch, we opened 19-C-0025 to collect blood and effusions (pleural and peritoneal) from patients with cancer enrolled on other protocols at the NCI. Additional clinical trials are under development at the concept stage or are under review by IRB. Within the WMB, I collaborate with Jung-min Lee and Stan Lipkowitz as Associate Investigator on several other clinical trials. I also collaborate with Diana Bianchi on a clinical trial to investigate the source of abnormal cfDNA in pregnant women with normal fetal karyotype. Another collaboration tested the metabolic effects of metformin in patients with Li Fraumeni Syndrome, and a larger international clinical trial is under development to test this drug as a strategy to prevent cancer in LFS patients.